-- FactSetが調査したアナリストによると、Caris Life Sciences（CAI）の平均投資判断は「買い」、平均目標株価は30.79ドルです。 （は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください：https://www..com/contact-us）
Related Articles
Asia
Seatrium Concludes the Divestment of Tugboat Fleet
Seatrium (SGX:5E2) completed the divestment of a fleet of 17 tugboats, according to a Monday filing with the Singapore Exchange.The divestment is expected to deliver over SG$50 million in annualized cost savings.Shares of the specialized engineering solutions company were down over 2% in Monday trading.
$SGX:5E2
Asia
China Nuclear Engineering's Attributable Profit Slides 36% in 2025
China Nuclear Engineering's (SHA:601611) attributable profit fell 36% to 1.32 billion yuan in 2025 from 2.06 billion yuan in 2024, according to a Saturday filing with the Shanghai bourse.Earnings per share at the nuclear power company decreased 37% to 0.36 yuan from 0.57 yuan in the previous year.Operating revenue declined 10% year over year to 101.9 billion yuan from 113.5 billion yuan.Shares decreased 2% during the midday break on Monday.
$SHA:601611
Asia
Junzheng Energy & Chemical's Attributable Profit Rises 18% in 2025; Shares Rise 4%
Inner Mongolia Junzheng Energy & Chemical's (SHA:601216) attributable profit rose 18% to 3.32 billion yuan in 2025 from 2.80 billion yuan in 2024, according to a Saturday filing with the Shanghai bourse.Earnings per share at the chemical manufacturer increased to 0.3932 yuan from 0.3323 yuan in the previous year.Operating revenue stayed flat at 25.2 billion yuan.Shares increased 4% during the midday break on Monday.
$SHA:601216